ENTA241220P20000
- 0.00
- 0.000.00%
Enanta Pharmaceuticals Newsroom
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported, And Analysts Assigned A US$18.13 Price Target
Enanta Pharmaceuticals (ENTA) Receives a Sell From J.P. Morgan
Enanta Pharmaceuticals' Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility
Enanta Pharmaceuticals | 10-K: FY2024 Annual Report
Oppenheimer Maintains Enanta Pharmaceuticals(ENTA.US) With Hold Rating, Cuts Target Price to $14
Express News | Enanta Pharmaceuticals Inc. : Oppenheimer Cuts Target Price to $14 From $16
Investors Don't See Light At End Of Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Tunnel And Push Stock Down 27%
Enanta Pharmaceuticals Is Maintained at Outperform by Baird
Express News | Enanta Pharmaceuticals Shares Fall 5% After Q4 Results
4 Analysts Assess Enanta Pharma: What You Need To Know
Enanta Pharma Analyst Ratings
Baird Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $20
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $21
Enanta Pharmaceuticals: Promising RSV Developments and Strong Immunology Pipeline Justify Buy Rating
Express News | Enanta Pharmaceuticals Inc : Baird Cuts Target Price to $20 From $26
Earnings Breakdown: Enanta Pharma Q4
Enanta Pharmaceuticals | 8-K: Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
Press Release: Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Fourth Quarter and Year-Ended September 30, 2024
Enanta Pharmaceuticals 4Q Loss/Shr $1.36 >ENTA
Enanta Pharmaceuticals 4Q Rev $14.6M >ENTA